Hemophilia A is the result of a deficiency of the Factor VIII protein that is an important protein for the coagulation of blood during injury. Approximately one in 5,000 males born in the United States has hemophilia.

A complication of human fVIII protein replacement therapy is the development of inhibitors, which occurs in 25% of treated patients. These inhibitors are the result of the immune system reacting towards the fVIII protein, since the patient's body considers it foreign.

LG888 is a novel chimeric fVIII protein molecule that promises to decrease the rate of inhibitor formation in Hemophilic patients. Lentigen has entered into collaboration with Emory University and Expression Therapeutics to develop LG888 as an alternative to the current form of fVIII protein therapy.